Bruton Tyrosine Kinase Degraders in B-Cell Malignancies

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract IA006: Resistance to BTK degraders2026
2. 2Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.2025 · 1 citations
3. 3Abstract 6069: Discovery and preclinical development of orally bioavailable potent BTK degrader, and its early clinical development for the treatment of relapsed and refractory B-cell malignancies2024
4. 4Discovery ofHighly Potent and Selective, Orally BioavailableBTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads2026
5. 5Abstract IA004: Targeting BTK in CLL and other B-cell Malignancies: Continuous Progress with a Continuous Therapy2026